XNAS · IRD
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Opus Genetics, Inc. Common Stock

Opus Genetics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$4.05
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
IRD
Opus Genetics, Inc. Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

40/ 100
Veridion Score
SELL BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IRD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IRD catalysts
About Opus Genetics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
28
Country
US

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.05
Last session
Day high
$4.05
Last session
Day low
$4.05
Last session
Previous close
$4.05
52W high
$5.75
-29.57% from high
52W low
$1.15
63% of range
Market cap
$336.9M
EPS
$-1.3800
Beta
1.18
Shares out
83.2M
Avg volume
854.2K
VWAP
$4.05
Last session
Price history computed in-house
1W
+10.96%
1M
+31.49%
3M
-0.98%
1Y
+252.17%
YTD
+101.49%
SMA 50 $3.75 · above
SMA 200 $3.59 · above
52W position 63%

IRD overview

Veridion Score
40
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IRD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IRD Form 4 filings
Public disclosures

Congress activity in IRD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for IRD in the cached public ledger.

Federal contracts

IRD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IRD in this window.
Lobbying spend

IRD lobbying filings, year to date.

Registered lobbying filings matched to Opus Genetics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IRD in this window.
Loading news for IRD
Analyst ratings
Sovereign unlock shows live analyst consensus for IRD.
Options
Sovereign unlock shows live options positioning for IRD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.